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CASE PRESENTATION
A 76–year-old white male was referred to the chronic
kidney disease clinic at the Brigham and Women’s
Hospital for evaluation of his kidney impairment of
longstanding duration. He was asymptomatic at the time
of presentation. His serum creatinine was 2.8 mg/dl and
his estimated glomerular filtration rate (GFR) using the
abbreviated modification of diet in renal disease study
group (MDRD) equation was 24-ml/min/1.73 m2. The
patient’s past medical history was remarkable for
long-term ingestion of anacin (at the time of
consumption, anacin comprised of phenacetin and acetyl
salicylic acid), which he bought as an over-the-counter
medication for recurrent headaches. Anacin started during
his college years and continued for several years (almost
20 years) because no other remedy was found for his
recurrent headaches. Although the patient could not recall
precisely, he estimated that his average daily consumption
of anacin was 2 g/day. Over the past 20 years he had
switched to acetaminophen – he estimated that he
ingested 3–4 tablets (1.5–2 g) of acetaminophen (single
ingredient) each day. He was diagnosed with
hypertension in 1977 and initiated on a thiazide diuretic.
However, since then the patient has also been treated
with atenolol 25 mg once daily, furosemide 40 mg once
daily, and losartan 50 mg twice daily. The patient also has
a history of gout that was first diagnosed in 1991 and
initially managed with colchicine and short courses of
sulindac (150 mg twice a day for 5 days) during attacks.
However, his gout got progressively worse to the extent
of having an attack every 3 weeks and was successfully
controlled with initiation of allopurinol 200 mg a day in
1999. In 1991, he was also noted to have mild abnormal
kidney function with a serum creatinine of 1.5 mg/dl and
an estimated GFR of 53 ml/min/1.73 m2. His kidney
function remained relatively stable for almost a decade.
However, since the beginning of 2000 his creatinine
gradually rose from 1.5 to 2.8 mg/dl (corresponding to fall
in estimated GFR from 53 to 23 ml/min/1.73 m2).
His current medications include: hydrochlorothiazide
12.5 mg once daily, furosemide 40 mg once daily, atenolol
25 mg once daily, losartan sodium 50 mg twice daily,
pantoprazole sodium 40 mg once daily, and a calcium
carbonate-based antacid (used on a pro re nata (PRN)
basis). Physical examination was unremarkable except for a
blood pressure of 144/74 mm Hg. Urinalysis revealed specific
gravity of 1.005 and trace protein, but was otherwise
negative. His urinary sediment was bland. The differential
diagnosis of his chronic kidney disease included analgesic
nephropathy, micro or macro vascular kidney disease, and
hyperuricemia-associated nephropathy. Computed tomogra-
phy (CT) scan evaluation of his kidneys without contrast
revealed bilateral shrunken and scarred kidneys (Figure 1).
There was high attenuation in the papillary regions bilaterally
representing mild papillary calcifications consistent with
analgesic nephropathy. This CT appearance fits with stage
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Figure 1 | CT scan of abdomen showing small indented, calcific
kidneys (SICK), a finding that is associated with analgesic
nephropathy. Using the classification proposed by Elseviers et al.1
this corresponds to stage III disease.
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three analgesic nephropathy using the CT imaging criteria
proposed by Elseviers et al.1 to diagnose analgesic nephro-
pathy (Figure 2). Laboratory data are shown in Table 1.
PRIMARY DIAGNOSIS
Analgesic nephropathy secondary to chronic multiple
analgesic abuse.
CLINICAL FOLLOW-UP
The patient was counseled to avoid analgesics. Although
analgesic abuse could have been the primary etiology for the
patient’s nephrotoxic injury, other causes for nephrotoxic
injury, such as gout and hypertension must also be
considered, although it is possible that the patient’s late
onset of hypertension and hyperuricemia could have been to
the consequence of his impaired kidney function. The
patient’s antihypertensive regimen was modified to achieve
better control of his blood pressure. At last follow-up, he
remained asymptomatic and with a blood pressure of 124/
72 mm Hg. He has been started on an angiotensin-converting
enzyme inhibitor (lisinopril 10 mg daily). His uric acid level
has improved from 9.4 to 4.3 mg/dl with dietary modification
and allopurinol therapy. His latest laboratory data reveal
kidney function as measured by serum creatinine of 2.4 mg/dl
(estimated GFR of 28 ml/min/1.73 m2) and blood urea
nitrogen is 61 mg/dl.
DISCUSSION
The incidence and prevalence of end-stage kidney disease has
been steadily increasing throughout the world. Early
identification of the modifiable risk factors and risk
prevention/reduction is of utmost importance in reversing
this trend. Analgesics and nonsteroidal anti-inflammatory
drugs (NSAIDS) are among the most widely and frequently
used drugs, particularly by among those at risk such as the
elderly population. Classic analgesics such as acetaminophen
(paracetamol), salicylates are commonly used for minor pain
syndromes, whereas NSAIDs are considered as effective and
well-tolerated first-line drugs for the management of various
arthritic and musculoskeletal disorders. Population studies
and WHO (World Health Organization) statistics indicate
that 10–50% of individuals have a history of musculoskeletal
disorders. Easy access to some of these over-the-counter
analgesics/combinations by the general public runs the risk of
unwarranted and unsupervised chronic intake. Many stu-
dies2,3 have suggested an association between chronic
ingestion of analgesics and kidney disease. Because of their
widespread use even a small increased risk of kidney disease
will have major public health implications.
Definition of analgesic nephropathy
A National Kidney Foundation position paper4 defines
analgesic nephropathy (AN) as ‘a disease resulting from the
habitual consumption over several years of a mixture
containing at least two anti-pyretic analgesics and usually
codeine or caffeine. It is characterized by kidney papillary
necrosis and chronic interstitial nephritis that leads to
insidious onset of progressive kidney failure’. However
habitual consumption of some nonopiate analgesics/NSAIDs
on their own has been associated with analgesic nephropathy.
This association of analgesic consumption with an increased
risk of kidney disease is controversial because of criticisms
regarding the design and execution of previous positive
studies. The majority of previously published papers on
analgesic nephropathy report the results from retrospective
case control design studies. These studies associating
analgesics with kidney disease are susceptible to several
sources of bias such as recall bias, selection bias, reverse
causality bias, interviewer bias, and (residual) confounding
bias. Indeed, a cohort study of analgesic use using data
obtained over 14 years from the Physicians’ Health Study5
concluded that moderate analgesic use (acetaminophen,
aspirin and other NSAIDS) in healthy men is not associated
with increased risk of kidney dysfunction. However, this
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Figure 2 | CT imaging criteria of analgesic nephropathy (adapted
from Elseviers et al.
Table 1 | Laboratory data
Complete blood count WBC (10.9 K/ml), HGB (11.7 g/dl), PLT (301 K/ml)
Renal chemistry Sodium (138 mmol/l), potassium (4.8 mmol/l)
Chloride (102 mmol/l), total CO2 (28 mmol/l)
BUN (61 mg/dl), creatinine (2.4 mg/dl)
Estimated GFR 28 ml/min
Bone chemistry Calcium (10.6 mg/dl), phosphate (2.5 mg/dl)
PTH (30 pg/ml)
Glucose 86 mg/dl
Urine microalbuminuria 6.2 mg/dl
Urine albumin/creatinine
ratio
202.6 mg albumin/g creatinine
Urine dipstick Urine pH 7.0, blood negative, and protein
trace
Specific gravity 1.005
Serum electrophoresis No abnormal electrophroetic pattern noted
BUN, blood urea nitrogen; HGB, hemoglobin; PLT, platelet; PTH, parathyroid
hormone; WBC, white blood cell.
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study also had limitations largely related to generalizability –
because the study population comprised of white male
physicians; it is not clear that the results would be applicable
to women or minority population.
Analgesics and chronic kidney injury
Until recently, analgesic nephropathy was regarded as a
relatively common cause of chronic kidney failure in
Australia, some parts of Europe and the United States.
However, strict regulations that limited the sale of phenacetin-
containing analgesic mixtures and other combined analgesics
over the past two decades appear to have resulted in a
markedly decreased incidence of AN. Nevertheless, because of
its insidious course, phenacetin-induced analgesic nephro-
pathy cases (such as in our patient) may still present clinically.
The majority of individuals are diagnosed 445 years of age,
suggesting that prolonged, regular ingestion of analgesics
could be important as risk factors in the etiology of AN.
Analgesic nephropathy is characterized by kidney papillary
necrosis and chronic interstitial nephritis. Both immunolo-
gical and nonimmunological mechanisms may play a role in
the pathogenesis of AN. The early phase changes of AN in
humans were first demonstrated in patients with normal
kidney function (as measured by serum creatinine) with a
history of phenacetin and acetyl salicylic acid consumption –
ingestion of a minimum of five tablets a day, for 5 years.6 In
comparison, Burrell et al.7 studied the effect of long-term
aspirin and acetaminophen administration in Fischer 344
rats.Histologic lesions seen in experimental-induced AN were
similar to those seen in humans. Medullary ischemia seems
to be the initiating event. Light and electron microscopy
revealed irreversible damage to medullary interstitium,
characterized by interstitial cell nuclear degeneration, abnor-
mal interstitial matrix, loss of medullary interstitial cells, and
increased collagen. The earliest changes involve sclerosis of
vasa recta capillaries and patchy tubular necrosis. Later
changes include areas of papillary necrosis and secondary
focal segmental glomerulosclerosis, cortical scarring, and
interstitial fibrosis. Papillary necrosis may also be the result of
reactive metabolic products of the drug or from the
accumulation of phospholipids in the papilla. Preexisting
analgesic nephropathy8 and acute pyelonephritis9 seem to
favor the development of NSAID-induced nephrotoxicity.
Diagnosis and screening
The early diagnosis of AN is very important because
progressive kidney injury could potentially be halted or even
reversed through discontinuation of drug use. Careful
questioning of the patient is key but often an accurate
history of analgesic consumption is difficult to obtain. The
exact duration, frequency, and the number of pills are often
forgotten or understated by the patient; hence additional
information from a close family member may be useful.
Conditions that prompt analgesic use such as recurrent
headaches, arthritic pains, or associated symptoms such as
history of peptic ulcer disease or ulcer-like symptoms should
be enquired and addressed to prevent relapse. Tablets
containing opiates or caffeine may cause dependence and
would need carefully monitored supportive withdrawal. An
early sign of AN is the loss of urinary concentration ability.
Hence, patients in need of long-term analgesic/NSAID
therapy for conditions such as inflammatory arthritis would
benefit from regular screening with urinary dipstick (to assess
specific gravity, proteinuria, etc) and serum creatinine
measurements. Clinical manifestations of AN are generally
nonspecific. It is a slowly progressive form of kidney failure
with no urinary sediment or with sterile pyuria or mild
proteinuria (o1.5 g/day) on urinalysis. Severe proteinuria
that exceeds 3.5 g/day is rare but can be secondary to
hemodynamically mediated glomerular injury. Some patients
may even have developed advanced kidney failure by the time
they present for the first time to a nephrologist.
Although papillary necrosis is present histologically in
almost all patients, it can be detected by radiologic imaging
only if part or all of the papilla has sloughed.10 Partial or total
papillary necrosis is observed in 25–40% of the patients.
Elseviers et al.1 demonstrated that CT scan without contrast
has a higher diagnostic performance than other modalities in
diagnosing AN.In their European multicenter study, a CT
scan observation of decreased kidney length along with either
bumpy contours or papillary calcifications in patients with an
appropriate analgesic history and mild to moderate kidney
impairment (creatinine ranging between 1.5 and4 mg/dl) had
a diagnostic sensitivity and specificity of 92 and 100%,
respectively, for AN. In end-stage kidney disease patients,
these figures were 90%. However, recently, the US National
Analgesic Nephropathy Study11 reported that the constella-
tion of CT findings (small, indented, calcific kidneys (SICK))
is quite infrequent in the US end-stage kidney disease
population. Their findings suggested that these CT abnorm-
alities did not occur among a sufficient proportion of heavy
analgesic users to justify the use of noncontrast enhanced CT
scan as a sensitive tool in the diagnosis of AN.
Role of acetaminophen
Acetaminophen is the primary metabolite of phenacetin.
Despite the clearly established association between phenace-
tin and AN, at present there is insufficient evidence to link
habitual acetaminophen use to AN. However, the consistency
of the results from existing epidemiological studies and the
observed apparent dose–response relationship suggests that
such a relationship cannot be excluded.12 Among 1700
healthy women who participated in Nurses’ health study13 in
United States, those consuming 43000 g of acetaminophen
had an odds ratio of 2.04 (CI 95% 1.28–3.24) less for a
decreased GFR of at least 30 mls/min/1.73 m2 over an 11-year
period compared to women consuming 100 g or more. In
contrast, Mihatsch et al.14 performed a very careful
morphological analysis of 1220 kidneys obtained from 616
adult autopsies between 2000 and 2003 and concluded that
classic analgesic nephropathy has disappeared some 20 years
after the removal of phenacetin from the analgesic market.
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This is despite the fact that mixed analgesics containing
acetaminophen, the main metabolite of phenacetin, have
continued to be popular. With the currently available
evidence acetaminophen remains the nonnarcotic analgesic
of choice for occasional use in patients with underlying
kidney disease. However, habitual intake of acetaminophen
should be discouraged and if indicated medically, a physician
should supervise its long-term use.4
Role of aspirin
Most studies demonstrate that long-term aspirin monother-
apy in therapeutic doses does not cause kidney injury in
patients with normal kidney function. However, aspirin
should be avoided in patients with impaired kidney function
and ‘at-risk groups’ such as those with volume deplete states,
glomerulonephritides, etc. There is no long-term adverse
kidney risk with the lower doses of aspirin recommended for
prevention of cardiovascular events and stroke.
Role of nonphenacetin-combined analgesics
An Ad Hoc Committee of the International Study Group on
Analgesics and Nephropathy15 critically reviewed the cur-
rently available data on the relationship between nonphena-
cetin-combined analgesics and AN. They concluded that at
present there is insufficient evidence to link nonphenacetin-
combined analgesics with nephropathy. They also observed
an absence of any association between the use of caffeine-
containing combined nonphenacetin analgesics and kidney
injury. However, some studies16 and experimental data raise
concerns of higher risk with these combinations.
Role of NSAIDs
The chronic use of NSAIDs in therapeutic doses is generally safe.
However, kidney papillary necrosis and chronic kidney failure
can occur in some patients. In contrast to the clearly defined ‘at-
risk population’ for acute kidney failure with NSAIDs, no data
delineate their exact risk in inducing papillary necrosis, chronic
kidney impairment, and end-stage kidney disease. Exposure to a
large cumulative dose of NSAID may lead to chronic kidney
disease in some cases. However, the percentage of patients
affected is small relative to the number of prescriptions written.
As COX-2 inhibitors are relatively new to the analgesic
armamentarium, their role in chronic kidney injury is uncertain.
Prolonged regular use of NSAIDS should be discouraged but if
deemed necessary, it should be closely monitored.
Analgesic syndrome
Analgesic nephropathy is a part of the wider clinical
‘analgesic’ syndrome, which includes neuropsychiatric, gas-
trointestinal, hematological, cardiovascular, and dermato-
logical manifestations in addition to the increased risk of
developing uroepithelial tumors. Although the major malig-
nancy that has been observed in association with AN is
transitional cell carcinoma, other cancers such as renal cell
carcinoma and sarcoma has also been reported in the
literature. Analgesic-associated tumors are more likely to be
multifocal and more malignant than those unrelated to
analgesics. These tumors are more likely of renal pelvic origin
with frequent accompaniment of renal papillary necrosis and
kidney dysfunction. A mean phenacetin consumption of
9.1 kg, a mean exposure time of 17 years, a mean induction
time of 22 years, and female sex have been reported as risk
factors for these tumors.17
CONCLUSION
It is important to highlight the potential adverse effects of
analgesic agents on the kidney. Patients who warrant chronic
therapy with these agents should be closely monitored for any
early signs of kidney injury. Early detection and removal of
the offending agent could halt or even reverse analgesic-
induced kidney injury. There is a pressing need for multi-
center trials to assess the true incidence of this problem and
to study the effects of various analgesic agents (alone and in
combination) in at-risk populations.
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